Epivax on Facebook
@EpiVax
RSS
News
EpiVax, Inc. forms Collaborative Research Agreement with Roche to Develop Tregitope Technology - December 2009
Providence’s Jewelry District: Growth hotspot? - November 2009
Polly Matzinger Fearless Scientist Award - November 2009
Open Registration for Spring 2010 URI Class - September 2009
Cicilline cites EpiVax as socially-conscious company - August 2009
“I believe that Tregitope technology represents a shift in thinking that may
allow the biotherapeutics industry to address a range of unanswered questions
related to side-effects based on immunogenicity; it truly has the potential to
provide important advances in minimizing unwanted immune responses through
tolerance induction.”
—Harald Kropshofer, Ph.D, Global Coordinator Immunosafety, F. Hoffmann-La Roche AG
" . . . The evidence suggests a new paradigm in which IgG epitopes
trigger regulatory T cell induction for the suppression of immune
response to protein therapeutics (like Factor VIII and monoclonal
antibodies), as well as for treatment of autoimmune diseases."
—Dr. David Scott, Professor, University of Maryland, Baltimore MD
"These results provide the rationale to develop novel therapies that
harness the potential of Tregs to regulate alloimmune responses
avoiding administration of toxic antibody therapy in humans."
—Dr. Mo Sayegh, Professor (Harvard Medical School, Brigham and Women's Hospital), Transplantation Research Center, Renal Division, Brigham and Women's Hospital and Children's Hospital Boston
"We conclude that the use of Tregitopes represents a promising strategy for antigen-specific, Treg-mediated modulation of capsid-specific T cell responses."
—Katherine High, M.D., Professor of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA
EpiVax, Roche Team Up to Develop Tregitope Technology
DECEMBER 1, 2009, Providence, RI
EpiVax, Inc. today announced a collaborative research agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) aimed at evaluating EpiVax's proprietary Tregitope technology, which could potentially reduce detrimental immune responses to certain drugs. In the course of the Roche-EpiVax collaboration, the EpiVax Tregitope technology will be evaluated for its effect on the immunogenicity of protein therapeutics.
Together, EpiVax and Roche will carry out in silico, in vitro and in vivo experiments aimed at establishing proof of concept. Under the agreement, Roche has a nonexclusive option to use Tregitope technology in its pipeline of protein therapeutic drugs with a right to a license the technology for specific products under pre-negotiated terms.
"Roche brings a wealth of experience, clinical expertise and resources to this collaboration. Working together, it is our intent to integrate the Tregitope technology into drugs that will improve human health on a global scale," said Dr. Anne De Groot, CEO and CSO of EpiVax.
©2008, EpiVax, Inc. All Rights Reserved. 146 Clifford St., Providence, RI 02903 ph: 401.272.2123 • fax: 401.272.7562 • Email Webmaster